Latest Conference Content

The second year of the extension study of Lemtrada (alemtuzumab) for multiple sclerosis reported positive interim results with 70% of patients not requiring a third course of treatment.

Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.

Patients with multiple sclerosis want to be actively engaged in their treatment decisions, which will help their long-term health and medication adherence, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.

The treatment landscape for multiple sclerosis continues to get more complex month to month, which makes biomarker discovery increasingly important for treating the disease, said Suhayl Dhib-Jalbut, MD, professor at the Rutgers University Robert Wood Johnson Medical School, during his session at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

Although the survival rate of natalizumab-associated progressive multifocal leukoencephalopathy (PML) is better than PML in HIV patients, long-term they may need some assistance and care, Ralf Gold, Ruhr University Bochum in Germany, said at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

Advanced imaging techniques are becoming necessary to further understanding of the progression of multiple sclerosis, according to presenters at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts, from September 10-13.

When choosing treatment for a patient, whether he or she has a clinically isolated syndrome or clinically definite multiple sclerosis, providers need to establish a collaborative relationship, according to speakers at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston, Massachusetts.

Terri Bernacchi, strategic consultant, audit and risk assessment, CIS, identified value-based contracting (VBC) as a forward-thinking approach for pricing and market needs. She discussed how VBC can improve formulary access, how it can impact the healthcare insurance exchanges, and how it can influence provider/payer reimbursement models.

What is value and how do we define it? In a panel discussion led by moderator Jean-Paul Gagnon, former senior director, Sanofi-Aventis, participants were asked to analyze the ways in which healthcare can shift from a fee-for-service model to one that focuses on value.

The Affordable Care Act (ACA) granted millions of uninsured Americans access to healthcare plans on the federal and state exchanges. Utilizing consumer research, Pamela Morris, director, Syndicated Research, Zitter Health Insights, described how both consumers and healthcare professionals are navigating these innovative insurance marketplaces.

There is increasing evidence that improving patient outcomes and cultivating value in the healthcare environment will require health economics and outcomes research (HEOR). Nicole Hengst, research director, Health Strategies Group, provided a unique perspective into some of the ways that payers can utilize HEOR to guide their decision-making practices.

Jeffrey Albright, director national accounts, Jazz Pharmaceuticals, said that many patients' access to specialty pharmaceutical products can be limited as health plans struggle to control costs. He provided important insight into pharmaceutical manufacturers' strategies, which aim to optimize appropriate patient access to the medications and products they need through various services that can provide reimbursement support.

While the fee-for-service reimbursement model has long been accepted as the standard model in healthcare, it must shift to one that focuses on value. Value-based reimbursement will encourage stakeholders to achieve the triple aim: improve patient experience, better manage population health, and reduce per-capita costs of healthcare so that patients receive more for the dollar spent, said Dan Sontupe, executive vice president, payer marketing & market access, The Cement Bloc.

Reports that artificial pancreas technology is advancing, and that multiple projects will soon start "at home" studies, created excitement at the 74th Scientific Sessions of the American Diabetes Association.

Studies presented at the American Diabetes Association's meeting in San Francisco took a deeper look at what the presence of fat does to overweight children. Researchers found that signs of trouble emerge early, with implications for the treatment of youths with type 1 diabetes, and those at risk of developing type 2 diabetes.

A symposium on the new drug class, SGLT2 inhibitors, drew plenty of interest from attendees at the American Diabetes Association meeting in San Francisco. SGLT2 inhibitors have gained notice, both for their ability to reduce A1C levels and for their potential to help patients lose weight.

A symposium that focused on the relationship between behavioral health and diabetes examined how the challenges of living with the disease wear on patients over time, ahead of results presented Sunday showing that much of what is diagnosed as "depression" in diabetes may not be. Presenters offered 3 models for better coordination of care.

Studies released at the 74th Scientific Sessions of the American Diabetes Association included results of programs to get patients to take more control over their own care.

A diabetes patient navigator program in Birmingham, Alabama, a joint project of the American Academy of Family Physicians Foundation and Sanofi US, resulted in lower A1C levels for its participants. Patients also reported higher levels of satisfaction in managing their disease.

Two studies presented at the American Diabetes Association's 74th Scientific Sessions show that evaluating diabetes risk and patient health by nation of origin and ethnic background yields richer insights into how the disease affects populations.​

Trimming the costs of diabetes to the healthcare system will take multiple strategies, but there's a lack of consensus on precisely how each will work. Are the new recommendations on statins worth the cost?

For years, the standard for treating type 2 diabetes mellitus (T2DM) has been step therapy. Patients are told to make changes in their diets and to exercise more. Then, most start metformin; if T2DM progresses, doctors add drugs from among the dozen other classes, either alone but typically in combination.

Some experts argue that overdiagnosis (OD) and overtreatment (OT) of cancer is common and increasingly costly. Others argue that current cure rates are high because of the screening processes currently in place. Both viewpoints were debated during the session "Overdiagnosis and Overtreatment in Cancer: Point/Counterpoint."

The health services research poster session held in the afternoon on the penultimate day of the 50th annual meeting of the American Society of Clinical Oncology (ASCO) presented different perspectives on issues that determine patient care decisions. This is an important discussion, especially in light of the recent report by The Wall Street Journal on WellPoint's effort to promote oncologist adherence to standardized treatment guidelines.

The discussion on value in cancer care was rekindled today at the 50th annual meeting of the American Society of Clinical Oncology, but this time on a global scale. The session, "ASCO/European CanCer Organisation (ECCO) Joint Session: Value and Cancer Care," saw participation from physicians and economists from around the world, with individual perspectives on defining value and the programs being developed to address the issue.

Velcade (bortezomib), developed by Millenium Pharmaceuticals, is a proteasome inhibitor that is currently approved for the treatment of multiple myeloma and relapsed mantle cell lymphoma. Several abstracts were presented at the annual meeting of the American Society of Clinical Oncology this year for its use in other indications.

The second day at the 50th annual meeting of the American Society of Clinical Oncology ended with a session entitled "Health Care in America in 2014: Current and Future Implications of the Patient Protection and Affordable Care Act" (PPACA). The presenters provided an overview of the recent and anticipated changes related to the PPACA as well as its timeline.

"The Value of Cancer Care and the Professional and Ethical Obligations of the Practicing Oncologist: A Debate" delved into the ethical issues raised by the economic reality of the rising costs of cancer care for the practicing oncologist.

ABT-199, the result of a collaboration between AbbVie and Genentech, is a selective, potent, orally available BCL-2 inhibitor. The drug is being developed in collaboration by the two companies for acute myelogenous leukemia and chronic lymphocytic leukemia (CLL).

While the incidence of cancer continues to grow, novel and targeted therapies being developed have seen much improved survival for even the deadliest of cancers. New innovations in cancer diagnosis and treatment are associated with high cost. Cancer therapy constitutes nearly 11% of the total healthcare budget, and it is rapidly growing.